AUS:BXN

Bioxyne Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czechia, Switzerland, France, Germany, and Japan. It operates through Pharmaceutical Manufacture and Wholesale Supply of Novel Medicines, Cannabis, Psilocybin, and MDMA; Manufacture and Distribution (Wholesale, Online, and Retail) of Consumer Health and Novel Food Products; and Wholesale of Patented Probiotics segments. The company offers active pharmaceutical ingredients and starting materials; plant-based food products, such as non-controlled cannabis extracts and cannabidiol; food grade mushroom extracts/psilocybin; medicinal and prescription cannabis products, including pastilles, vape, oral mucosal oils, flower, and suppositories; SL-NAD+ wafers; MDMA; white label manufactured wellness products; health and wellness supplements; and nootropic and skincare products. It also provides Lactobacillus fermentum VRI-003 PCC, a probiotic formulation for gastrointestinal health and immunity; Progastrim for gut and immune health; and proTract for atopic dermatitis. In addition, the company is involved in the contract manufacturing of final dose form products, including capsules, tablets, inhalables, oral solutions, and herbal preparations; import, export, manufacture, and supply of controlled drugs and medicinal products; research and development of formulations, products, and processes related to health, wellness, and medicine; and provision of telemedicine services. Further, it operates CanXChange, a machine-learning powered B2B wholesale and custody technology platform. The company offers its products to cultivators, manufacturers, pharmacies, clinics, and patients under the Breathe Life Science, Dr Watson, Mirai Solution, and Apothecary CBD brands. It sells its products through wholesale, retail, and online. Bioxyne Limited is headquartered in Sydney, Australia.